Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium

Davide Seripa, Vincenzo Solfrizzi, Bruno P. Imbimbo, Antonio Daniele, Andrea Santamato, Madia Lozupone, Giovanni Zuliani, Antonio Greco, Giancarlo Logroscino, Francesco Panza

Research output: Contribution to journalArticle

Abstract

Small molecular weight compounds able to inhibit formation of tau oligomers and fibrils have already been tested for Alzheimers disease (AD) treatment. The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+). MT chloride (also known as methylene blue) was investigated in a 24-week Phase II study in 321 mild-to-moderate AD patients at the doses of 69, 138, and 228 mg/day. This trial failed to show significant positive effects of MT in the overall patient population. The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected patients and cerebral blood flow in mildly affected patients. A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed. Phase III clinical trials on this novel TAI in AD and in the behavioral variant of frontotemporal dementia are underway.

Original languageEnglish
Pages (from-to)259-277
Number of pages19
JournalExpert Review of Neurotherapeutics
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 3 2016

Fingerprint

Alzheimer Disease
Methylene Blue
Cerebrovascular Circulation
Frontotemporal Dementia
Phase III Clinical Trials
Poisons
Therapeutics
Molecular Weight
Pharmaceutical Preparations
Population

Keywords

  • Alzheimer's disease
  • dementia
  • immunotherapy
  • leucomethylthioninium
  • methylthioninium
  • microtubule-stabilizing agents
  • tau aggregation inhibitors
  • tau phosphorylation inhibitors
  • tau protein
  • TRx0237

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Tau-directed approaches for the treatment of Alzheimers disease : Focus on leuco-methylthioninium. / Seripa, Davide; Solfrizzi, Vincenzo; Imbimbo, Bruno P.; Daniele, Antonio; Santamato, Andrea; Lozupone, Madia; Zuliani, Giovanni; Greco, Antonio; Logroscino, Giancarlo; Panza, Francesco.

In: Expert Review of Neurotherapeutics, Vol. 16, No. 3, 03.03.2016, p. 259-277.

Research output: Contribution to journalArticle

Seripa, D, Solfrizzi, V, Imbimbo, BP, Daniele, A, Santamato, A, Lozupone, M, Zuliani, G, Greco, A, Logroscino, G & Panza, F 2016, 'Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium', Expert Review of Neurotherapeutics, vol. 16, no. 3, pp. 259-277. https://doi.org/10.1586/14737175.2016.1140039
Seripa, Davide ; Solfrizzi, Vincenzo ; Imbimbo, Bruno P. ; Daniele, Antonio ; Santamato, Andrea ; Lozupone, Madia ; Zuliani, Giovanni ; Greco, Antonio ; Logroscino, Giancarlo ; Panza, Francesco. / Tau-directed approaches for the treatment of Alzheimers disease : Focus on leuco-methylthioninium. In: Expert Review of Neurotherapeutics. 2016 ; Vol. 16, No. 3. pp. 259-277.
@article{4d9f26db71584a46a28b97e20acbda9f,
title = "Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium",
abstract = "Small molecular weight compounds able to inhibit formation of tau oligomers and fibrils have already been tested for Alzheimers disease (AD) treatment. The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+). MT chloride (also known as methylene blue) was investigated in a 24-week Phase II study in 321 mild-to-moderate AD patients at the doses of 69, 138, and 228 mg/day. This trial failed to show significant positive effects of MT in the overall patient population. The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected patients and cerebral blood flow in mildly affected patients. A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed. Phase III clinical trials on this novel TAI in AD and in the behavioral variant of frontotemporal dementia are underway.",
keywords = "Alzheimer's disease, dementia, immunotherapy, leucomethylthioninium, methylthioninium, microtubule-stabilizing agents, tau aggregation inhibitors, tau phosphorylation inhibitors, tau protein, TRx0237",
author = "Davide Seripa and Vincenzo Solfrizzi and Imbimbo, {Bruno P.} and Antonio Daniele and Andrea Santamato and Madia Lozupone and Giovanni Zuliani and Antonio Greco and Giancarlo Logroscino and Francesco Panza",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/14737175.2016.1140039",
language = "English",
volume = "16",
pages = "259--277",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Tau-directed approaches for the treatment of Alzheimers disease

T2 - Focus on leuco-methylthioninium

AU - Seripa, Davide

AU - Solfrizzi, Vincenzo

AU - Imbimbo, Bruno P.

AU - Daniele, Antonio

AU - Santamato, Andrea

AU - Lozupone, Madia

AU - Zuliani, Giovanni

AU - Greco, Antonio

AU - Logroscino, Giancarlo

AU - Panza, Francesco

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Small molecular weight compounds able to inhibit formation of tau oligomers and fibrils have already been tested for Alzheimers disease (AD) treatment. The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+). MT chloride (also known as methylene blue) was investigated in a 24-week Phase II study in 321 mild-to-moderate AD patients at the doses of 69, 138, and 228 mg/day. This trial failed to show significant positive effects of MT in the overall patient population. The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected patients and cerebral blood flow in mildly affected patients. A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed. Phase III clinical trials on this novel TAI in AD and in the behavioral variant of frontotemporal dementia are underway.

AB - Small molecular weight compounds able to inhibit formation of tau oligomers and fibrils have already been tested for Alzheimers disease (AD) treatment. The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+). MT chloride (also known as methylene blue) was investigated in a 24-week Phase II study in 321 mild-to-moderate AD patients at the doses of 69, 138, and 228 mg/day. This trial failed to show significant positive effects of MT in the overall patient population. The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected patients and cerebral blood flow in mildly affected patients. A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed. Phase III clinical trials on this novel TAI in AD and in the behavioral variant of frontotemporal dementia are underway.

KW - Alzheimer's disease

KW - dementia

KW - immunotherapy

KW - leucomethylthioninium

KW - methylthioninium

KW - microtubule-stabilizing agents

KW - tau aggregation inhibitors

KW - tau phosphorylation inhibitors

KW - tau protein

KW - TRx0237

UR - http://www.scopus.com/inward/record.url?scp=84959325967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959325967&partnerID=8YFLogxK

U2 - 10.1586/14737175.2016.1140039

DO - 10.1586/14737175.2016.1140039

M3 - Article

AN - SCOPUS:84959325967

VL - 16

SP - 259

EP - 277

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -